23-Propyl-5,7,14,17,20,23,26,33-octazapentacyclo[23.2.2.214,17.12,6.18,12]tritriaconta-1(27),2(33),3,5,8,10,12(32),25,28-nonaen-19-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 23-Propyl-5,7,14,17,20,23,26,33-octazapentacyclo[23.2.2.214,17.12,6.18,12]tritriaconta-1(27),2(33),3,5,8,10,12(32),25,28-nonaen-19-one
• 英文别名: 23-propyl-5,7,14,17,20,23,26,33-octazapentacyclo[23.2.2.214,17.12,6.18,12]tritriaconta-1(27),2(33),3,5,8,10,12(32),25,28-nonaen-19-one
• 化学式: C₂₈H₃₆N₈O
• 分子量: 500.647
• InChiKey: IXYCJHGBVPWYJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  37
• 可旋转键数：
  2
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  89.5
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] MACROCYLIC PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDINE MACROCYCLIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015150555A1

  公开（公告）日：2015-10-08

  The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式(I)的取代大环嘧啶衍生物，其中变量具有如权利要求中所定义的含义。根据本发明的化合物具有EF2K抑制活性，并且可选地也具有Vps34抑制活性。本发明还涉及制备这些新颖化合物的方法，包括将所述化合物作为活性成分的药物组合物以及将所述化合物用作药物的使用。
• Macrocylic pyrimidine derivatives
  申请人：Janssen Pharmaceutica NV

  公开号：US10017509B2

  公开（公告）日：2018-07-10

  The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式 (I) 的取代大环嘧啶衍生物 其中的变量具有权利要求中定义的含义。根据本发明的化合物具有 EF2K 抑制活性和可选的 Vps34 抑制活性。本发明进一步涉及制备此类新型化合物的工艺、包含所述化合物作为活性成分的药物组合物以及所述化合物作为药物的用途。
• MACROCYLIC PYRIMIDINE DERIVATIVES
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP3126364B1

  公开（公告）日：2018-02-07